tm logo
ROSLINCT
Live/Pending
NOTICE OF ALLOWANCE - ISSUED

issued

on 09 Jul 2024

Last Applicant/ Owned by

9 Little France Road

Edinburgh

GB

EH164UX

Serial Number

97913008 filed on 28th Apr 2023

Registration Number

N/A

Correspondent Address

Benjamin P. Harbuck

Benjamin P. Harbuck DENTONS US LLP

CHICAGO, IL 60604

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

ROSLINCT

Scientific research, development and testing services in the fields of cell therapy and gene therapy; research and development of new products for others in the fields of cell therapy and gene therapy; pharmaceutical and biopharmaceutical research and development services in the fields of cell therapy and gene therapy; scientific consultancy services in the fields of designing, building, testing a Read More

Classification Information


Class [044]
Medical, Beauty & Agricultural Services


Medical services relating to the removal, treatment and processing of stem cells; medical services, namely, stem cell therapy services; medical services, namely, gene therapy services; stem cell bank services, namely, stem cell storage; information, advisory and consultancy services related to the aforesaid


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [042]
Computer & Software Services & Scientific Services


Scientific research, development and testing services in the fields of cell therapy and gene therapy; research and development of new products for others in the fields of cell therapy and gene therapy; pharmaceutical and biopharmaceutical research and development services in the fields of cell therapy and gene therapy; scientific consultancy services in the fields of designing, building, testing and validating processes and systems for use in cell therapy and gene therapy services; design and development of computer hardware and software in the biopharmaceutical, cell therapy and gene therapy fields; development of computer databases in the biopharmaceutical, cell therapy and gene therapy fields; scientific development of custom assays for cell therapy and gene therapy; stem cell research services; information, advisory and consultancy services related to the aforesaid


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [041]
Education and Entertainment Services


Education and training services, namely, classes, seminars, tutorials, conferences and workshops in the fields of cell therapy and gene therapy; provision of online education, training and teaching services, namely, classes, non-downloadable webinars and tutorials in the fields of cell therapy and gene therapy; arranging, organising and conducting of colloquiums, conferences, congresses, seminars and symposiums in the fields of cell therapy and gene therapy; publication of books, scientific papers and texts in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [035]
Advertising, Business & Retail Services


Business information, consultancy and management services in the fields of designing, building, testing and validating processes and systems for use in cell therapy and gene therapy services; business consultation services in the nature of technology transfer advice and management in the fields of cell therapy and gene therapy; advertising, marketing and promotional services in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [016]
Paper Goods and Printed Material


Paper signs, cardboard signs, and printed matter, namely, brochures, books and journals in the fields of cell therapy and gene therapy; paper instructional and teaching material, except apparatus, in the fields of cell therapy and gene therapy


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [009]
Computer & Software Products & Electrical & Scientific Products


Scientific apparatus and instruments, namely, bioreactors for cell culturing, laboratory incubators and laboratory centrifuges for use in the development, testing, training and, manufacturing of stem cells and related cell and gene therapy products; downloadable computer software and hardware for use in the development, testing, training and, manufacturing of stem cells and related cell and gene therapy products; replacement and structural parts and fittings for the aforesaid goods


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [040]
Treatment & Processing of Materials Services


Contract manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; contract manufacturing in the fields of cell therapy and gene therapy; custom manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; custom manufacturing in the fields of cell therapy and gene therapy; custom fabrication and production of cells for others; manufacturing process consulting in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 97913008

Mark Type

No Service Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
09th Jul 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
14th May 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14th May 2024PUBLISHED FOR OPPOSITION
24th Apr 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05th Apr 2024APPROVED FOR PUB - PRINCIPAL REGISTER
02th Apr 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
02th Apr 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
02th Apr 2024TEAS/EMAIL CORRESPONDENCE ENTERED
30th Jan 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
30th Jan 2024NON-FINAL ACTION E-MAILED